ArQule (ARQL) Misses Q4 EPS by 1c, Revenues Beat; Offers FY19 EPS Guidance Above Consensus, FY19 Revenue Guidance Below Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
ArQule (ARQL) PT Raised to $8 at Oppenheimer
March 8, 2019 9:11 AM ESTOppenheimer analyst Hartaj Singh raised the price target on ArQule (NASDAQ: ARQL) to $8.00 (from $7.00) while maintaining a Outperform rating following the company's 4Q report. Results were in line with Oppenheimer's estimates and expectations. Singh has updated the model for 2019, with estimates in line with... More
Needham & Company Reiterates Bullish View on ArQule (ARQL) as Partial Response Seen in C481S Mutant Patient with ARQ-531
March 7, 2019 1:44 PM ESTNeedham & Company analyst Chad Messer reiterated a Buy rating and $7 price target on ArQule (NASDAQ: ARQL) after a partial response was observed in ibrutinib refractory C481S mutant patient with ARQ-531.
"ArQule reported that the first patient treated in the current 7th... More
ArQule (ARQL) Surges 40% Following Results, Update
March 7, 2019 9:27 AM ESTArQule (NASDAQ: ARQL) is gaining 40% in pre-open trade following results and update.
... More